15 years+ Industry research experience. Only Company which focuses on small product segmentation reports.
Global next generation sequencing market size is projected to be worth USD 36 Billion by 2026, expanding at CAGR of 18.2% during the forecast period (2022 - 2030), The market was valued at USD 6.47 Billion in 2021.
The term next generation sequencing (NGS) is an extremely parallel sequencing technology that provides ultra-high throughput, speed, and scalability. It is also identified as "high-throughput sequencing," referring to a range of modern sequencing technologies. This technology is utilized to determine the order of nucleotides in complete genomes or targeted regions of DNA or RNA, and also this technology makes it potential to sequence RNA and DNA in a dependable and cost-effective way. The requirements for next-generation sequencing are increasing overall in medical appliances as they are generally used in functional genomics to test DNA and RNA samples.
Due to the continuous technological advancements in sequencers, the initiation of convenient, portable, and efficient NGS platforms are allowed that is capable of giving quick and exact outcomes and showing a better turnaround time where major players are mostly focused on the research & development of these products to make stronger their growth positions and revenues. This is driving the NGS market growth worldwide. Also, the enhancement in genome mapping activities is boosting the global next-generation sequencing market in the near future. Moreover, the major factors such as declining costs of genome sequencing and rising occurrence of cancer, the expansion in NGS platforms, and the growing usage of next-generation sequencing in cancer research centers are fuelling the market growth in the NGS across the globe.
Importantly, government associations are sequencing millions of genomes for the advancement of research as well as diagnosing and treating cancer disease and other diseases where large sequencing initiatives are likely to offer positive growth opportunities for key companies during the forecast period.
On the other hand, several academic & research institutes are facing budget limitations while purchasing and using advanced and premium-priced equipment and technologies, as academic research & development in emergent countries is usually dependent on external funding. Due to this, the development of advanced research amenities is hindered in the academic and research institutes in emergent countries. This, in turn, is impeding the market globally during the forecast period.
North America is leading the global next-generation sequencing market, followed by the European region, due to factors such as the growth in the utilization of next-generation sequencing in genomics research and diagnostics. Also, the launching of the latest products is propelling the market growth in the region.
Furthermore, the Asia-Pacific region is anticipated to have the largest market share in the forthcoming years as a result of the bigger investment by pharma and biotech industries is estimated to increase the user’s demand.
Various players operating in the next-generation sequencing market cover Genomatix GmbH, Agilent Technology, PierianDx; DNASTAR Inc., Illumina, Eurofins GATC Biotech GmbH, QIAGEN, F. Hoffman-La Roche Ltd., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, Bio-Rad Laboratories Inc., BGI Group, and Perkin Elmer Inc.
For example, PierianDx has strengthened its clinical and laboratory facility to effectively diagnose and cure cancer and other chronic diseases. In 2019, the company had raised a $26,870,702 series B round from ATW Partners, RTI International, and SJF Ventures.
Global Next Generation Sequencing (NGS) Market: By Application
Global Next Generation Sequencing (NGS) Market: By Technology
Global Next Generation Sequencing (NGS) Market: By End-User
Global Next Generation Sequencing (NGS) Market: Regional Segmentation Analysis
Global contract research organization (CRO) market was valued at around USD 43.7 Billion in year 2021 and is anticipated to generate revenue of almost USD 58.3 Billion by the end of year 2030. The global industry is growing at a healthy CAGR of approximately 9% during the 2021-2026. The latest report by Vertex Market Research on the global Contract Research Organization (CRO) Market offers insights and analysis regarding the various aspects and dynamics throughout the study period while providing their impacts on the overall market’s growth.
The contract research organizations (CRO) offer help to the biotechnology, pharmaceutical, and medical device companies. Factors such as the rising patient population, increasing demand for effective drugs and healthcare devices, and high expenditure of product expansion are responsible for the contract research organization market growth across the globe. Furthermore, augmented outsourcing services of research, the evolving research and development costs, and development programs, and expansion number of clinical trials are expected to fuel the growth of the market during the forecast period. The patent expiries leading to the general competition and severe demands from regulators will have a constructive impact on the bottom lines of pharmaceutical industries which is also contributing to the market.
This report segments the global contract research organization (CRO) market as follows:
Global Contract Research Organization (CRO): By Type
Global Contract Research Organization (CRO): By Application
Global Contract Research Organization (CRO): Regional Segmentation Analysis
Global cell culture media market is expected to be worth USD 1,524 Million by 2030, increasing at an 8.5% CAGR during the forecast period (2022 - 2030). The market was valued at USD 876.3 Million in 2021.
In microbiological laboratories and research centers, the culture media is used for growing and controlling cells. The cell culture media is constituted of a group of vitamins, inorganic salts, amino acids, glucose for the energy source, and serum for the source of growth, attachment factors & hormones.
The market report analysis is based on both primary and secondary data sources. Primary sources include interviews conducted with various industry analysts, suppliers and distributors, whereas secondary sources include data collected from government websites and annual report of companies and other relevant documents.
All the information provided in the study is corroborated by the global market leaders. The report underscores the use of top-down approach to evaluate figures for each market segment, which are then validated by leveraging the bottom-up approach.
The culture media market is growing due to quick development in the sector of biopharmaceuticals, biotechnology, stem cell research, and oncology. In addition, the high requirement used for the culture media, and technological developments are the most important factors fuelling the market growth in the global cell culture media. Furthermore, innovation in the life science sector and growth in funding & investments in research and development is stimulating market growth.
Also, the culture media market share is anticipated to increase in the future, owing to accessibility and availability of customized and specialty media and the increase in adoption of the cell culture in the emerging markets.
However, the existence of potential and promising markets is likely to offer beneficial opportunities to the market industries in the global culture media market during the forecast period.
On the other hand, the ethical & scientific worry regarding culture media and the shortage of experienced professionals will hamper the growth of the cell culture media market.
The geographical split of the cell culture media market comprises North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. In terms of revenue, North America has the highest market share in the global cell culture media market due to the augment in developments regarding cell culture media, the increase in research and development investments, and higher requirements for cell culture media. This, in turn, is propelling the market growth in the region of North American.
The market-based in Asia-Pacific has the largest growth prospective due to multiple factors such as the growth in the healthcare sector & research expenses, the major economic progress and the availability of research amenities are driving the market of the cell culture media in the region during the forecast period.
The several market players in the global cell culture media market include Life Technologies, Avantor Performance Materials LLC, Sigma-Aldrich, Bio-Rad Laboratories Inc., Cell Essentials Inc., Atlanta Biologicals, Becton, Dickinson and Company, Caisson Laboratories Inc., Corning Incorporated, Cell Culture Technologies LLC, HiMedia Laboratories, Fujifilm Holdings, Lonza Group, Vitro Diagnostics Inc., Sartorius AG, Novozymes Biopharma US Inc., Merck & Co. Inc., Sera Scandia A/S, Thermo Fisher Scientific Inc., Takara Bio Inc., Cyagen Biosciences Inc., Analytical Biological Services Inc., among others.
This report segments the global cell culture media market as follows:
Global Cell Culture Media Market: By Reagent Type
Global Cell Culture Media Market: By Type
Global Cell Culture Media Market: By End-User
Global Cell Culture Media Market: By Application
Global Cell Culture Media Market: Regional Segmentation Analysis
The Global Cancer Gene Therapy Market was valued at USD 558.24 million in 2019 and is estimated to reach USD 921.8 million by 2030, expanding at a CAGR of 32.6% during the forecast period, from 2020 to 2030.
Cancer gene therapy refers to the cancer treatment where therapeutic DNA is being introduced into the gene of the patient having cancer. The most commonly used technique for cancer gene therapy is replacing a mutated gene causing cancer with a healthy copy of the gene. Another technique used is the inactivation of a gene that is not functioning well. Lately, a new technique has been introduced to the cancer gene therapy market that is the insertion of new genes into the body which will help in fighting against the cancer cells. Due to its success rate in preclinical as well as clinical trial stages, cancer gene therapy is gaining recognition all over the world.
The major factors such as the growing incidences of cancer population, favorable government initiatives, rising elderly population, and growing funds for research and development projects for cancer gene treatment are driving the growth of the global cancer gene therapy market. Other than this, ethical approval of cancer gene treatment and the rising recognition of DNA vaccines are propelling the global cancer gene therapy market over the forecast period. Furthermore, numerous cancer gene treatment products are in clinical trial phases. This, in turn, will continue to have a positive influence on the market. On the other hand, the available market in emergent countries, industrial developments leading to improved adoption, and ethical approval of cancer gene therapy treatment will create lucrative opportunities for the global market of cancer gene therapy market.
However, factors such as less awareness, high expenditure for cancer gene treatment, and unfavorable immune responses are likely to hamper the market growth of cancer gene therapy.
North America in terms of revenue is leading the global cancer gene therapy market, owing to the high geriatric population and industrial development in this region. Similarly, Europe is dominating the global market of cancer gene therapy. Moreover, the Asia-Pacific is likely to experience the highest growth in the cancer gene therapy market because of rising government programs, and growing cost-cutting measures and development in healthcare infrastructure. Also, other factors like the large population of patients, growing research and development investments, and increasing government funding in developing countries are responsible for market expansion.
Some key market players in the global cancer gene therapy market include Vigene Biosciences, Cell Genesys, Sirion Biotech, Adaptimmune, Advantagene, Bluebird Bio, GenVec, Cobra, BioCancell, Cellectis, Sarepta Therapeutics, Epeius Biotechnologies, Uniqure, Introgen Therapeutics, ZIOPHARM Oncology, Finvector MultiVir, Shenzhen SiBiono GeneTech, GlaxoSmithKline, Merck, and Celgene.
This report segments the global cancer gene therapy market as follows:
Global Cancer Gene Therapy Market: By Type
Global Cancer Gene Therapy Market: By Product
Global Cancer Gene Therapy Market: Regional Segmentation Analysis